Product Images Wixela Inhub
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 18 images provide visual information about the product associated with Wixela Inhub NDC 70518-2501 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Remedy_Label - Remedy Label
Wixela Inhub is an inhalation powder medication with the active ingredients Fluticasone Propionate and Salmeterol, which are used to treat asthma and chronic obstructive pulmonary disease (COPD). The package contains 60 doses at a strength of 250mcg/50 mcg. The medication is manufactured by Mylan in Morgantown, WV 26505, and repackaged by RemedyRepack Inc. in Indiana, PA 15701. The directions for use are specified in the package insert, and the medication should be stored at a temperature range of 20-26°C (63-77°F) with excursions permitted to 15-30°C (59-86°F) [See USP]. The expiration date and lot number are not available. It is advised to keep this and all medication out of the reach of children.*
Instructions for Use Figure A - image 01
Fluticasone Propionate Structural Formula - image 02
Salmeterol Zinofoate Structural Formula - image 03
Figure 1. Mean Percent Change from Baseline in FEV1 in Subjects with Asthma Previously Treated with Either Inhaled Corticosteroids or Salmeterol (Trial 1) - image 04
This appears to be a combination of numerical values and text related to a drug treatment study. The text mentions "Fluicasone propionate" and "Saimeterol" being taken twice daily, and has a chart with weeks 0-12 and an endpoint. The rest of the text is mostly illegible due to formatting issues and errors.*
Figure 2. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - image 05
This appears to be data on the change in FEV (Forced Expiratory Volume) for different treatment groups on the first day of treatment. The treatment groups include Fluticasone propionate and Salmeterol inhaler, as well as a placebo group. The data includes the number of participants in each group and the dosage. However, the rest of the text is not-readable due to errors.*
Figure 3. Percent Change in Serial 12-Hour FEV1 in Subjects with Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - image 06
Figure 4. Predose FEV1: Mean Percent Change from Baseline in Subjects with Chronic Obstructive Pulmonary Disease - image 07
This is a study evaluating the effect of Fluticasone Propionate and Salmeterol inhalation powder in improving lung function in patients with a baseline forced expiratory volume (FEV) of 1207 mL. The study had a placebo group and a group receiving Salmeterol alone. The results recorded the changes in FEV over 24 weeks with the inhalation powder group showing improvement in their lung function.*
Figure 5. Two-Hour Postdose FEV1: Mean Percent Changes from Baseline over Time in Subjects with Chronic Obstructive Pulmonary Disease - image 08
The text is a table showing the change in forced expiratory volume (FEV) for patients receiving various treatments. The treatments include Fluticasone propionate and Salmeterol inhalation, Fluticasone propionate only, and a Placebo. The data includes the daily dose, with the endpoint of the study being between day 1 and week 24. The table also includes the number of patients (N) for each treatment group.*
Instructions for Use Figure B - image 09
Instructions for Use Figure C - image 10
Instructions for Use Figure D - image 11
Instructions for Use Figure F - image 12
Instructions for Use Figure G - image 13
Instructions for Use Dose Counter Figure 1 - image 14
Instructions for Use Dose Counter Figure 2 - image 15
Instructions for Use Dose Counter Figure 3 - image 16
Instructions for Use Figure E - image 17
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.